Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.80 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.80 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.80 |
| ▸ | HMGCR | P04035 | 5/20 | 0.77 |
| ▸ | RXRA | P19793 | 3/20 | 0.77 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.45 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.45 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.45 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.45 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.45 |
| ▸ | PGR | P06401 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | CCKAR | P32238 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30881627 | 1.00 | NR4A2 (0.80) | NR4A2PDE4DNR1I2HMGCRRXRA | |
| SCHEMBL14273685 | 1.00 | NR4A2 (0.80) | NR4A2PDE4DNR1I2HMGCRRXRA | |
| SCHEMBL30291805 | 1.00 | NR4A2 (0.80) | NR4A2PDE4DNR1I2HMGCRRXRA | |
| SCHEMBL30203740 | 1.00 | NR4A2 (0.80) | NR4A2PDE4DNR1I2HMGCRRXRA | |
| SCHEMBL14273684 | 1.00 | NR4A2 (0.80) | NR4A2PDE4DNR1I2HMGCRRXRA | |
| SCHEMBL10153166 | 1.00 | NR4A2 (0.80) | NR4A2PDE4DNR1I2HMGCRRXRA | |
| SCHEMBL2904607 | 1.00 | NR4A2 (0.80) | NR4A2PDE4DNR1I2HMGCRRXRA | |
| SCHEMBL1582433 | 1.00 | NR4A2 (0.80) | NR4A2PDE4DNR1I2HMGCRRXRA | |
| SCHEMBL1582437 | 1.00 | NR4A2 (0.80) | NR4A2PDE4DNR1I2HMGCRRXRA | |
| SCHEMBL14262755 | 1.00 | NR4A2 (0.80) | NR4A2PDE4DNR1I2HMGCRRXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550596-B2 | Method of producing ethyl (3R, 5S, 6E)-7-[2 cyclopropyl-4-(fluorophenyl) quinoline-3-yl]-3, 5-dihydroxy-6-heptenoate | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2009-06-23 | — | — | US | claimed |
| EP-1472227-B1 | PROCESS FOR THE MANUFACTURE OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2016-04-27 | — | — | EP | disclosed |
| US-7692018-B2 | Process for producing high purity 3,5-dihydroxy-6-heptenoic acid derivative | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-04-06 | — | — | US | disclosed |
| US-20090299065-A1 | PROCESS FOR THE MANUFACTURE OF ORGANIC COMPOUNDS | CHEN GUANG-PEI | 2009-12-03 | — | — | US | disclosed |
| US-7572917-B2 | Process for the manufacture of organic compounds | NOVARTIS AG (CH) | 2009-08-11 | — | — | US | disclosed |
| US-7550596-B2 | Method of producing ethyl (3R, 5S, 6E)-7-[2 cyclopropyl-4-(fluorophenyl) quinoline-3-yl]-3, 5-dihydroxy-6-heptenoate | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2009-06-23 | — | — | US | disclosed |
| US-20060229451-A1 | Process for producing high purity 3,5-dihydroxy-6-heptenoic acid derivative | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2006-10-12 | — | — | US | disclosed |
| US-6909003-B2 | Process for the manufacture of organic compounds | NOVARTIS AG (CH) | 2005-06-21 | — | — | US | disclosed |
| US-6835838-B2 | Condensation of silicon compounds with aldehydes in the presence of titanium catalysts in solvents, then reducing and hydolyzing to form drugs used for prophylaxis of atherosclerosis or as enzyme inhibitors | NOVARTIS AG (CH) | 2004-12-28 | — | — | US | disclosed |
| US-20040249154-A1 | Process for the manufacture of organic compounds | CHEN GUANG-PEI (US) | 2004-12-09 | — | — | US | disclosed |
| US-20030233001-A1 | Process for the manufacture of organic compounds | NOVARTIS AG (CH) | 2003-12-18 | — | — | US | disclosed |
| US-20030208072-A1 | Process for the manufacture of organic compounds | NOVARTIS AG (CH) | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090299065-A1 | PROCESS FOR THE MANUFACTURE OF ORGANIC COMPOUNDS | HSD11B1, HSD3B1, HSD11B2 | NR4A2 2928/4885PDE4D 4198/4885NR1I2 4403/4885 |
| US-20040249154-A1 | Process for the manufacture of organic compounds | HSD11B1, HSD3B1, HSD11B2 | NR4A2 2928/4885PDE4D 4198/4885NR1I2 4403/4885 |
| US-20060229451-A1 | Process for producing high purity 3,5-dihydroxy-6-heptenoic acid derivative | ADH1A, ADH1C, DHCR7 | NR4A2 1287/4885PDE4D 1779/4885NR1I2 641/4885 |
| US-20030208072-A1 | Process for the manufacture of organic compounds | HSD11B1, HSD3B1, HSD11B2 | NR4A2 2928/4885PDE4D 4198/4885NR1I2 4403/4885 |
| US-20030233001-A1 | Process for the manufacture of organic compounds | CYP11B2, CYP11B1, HSD17B12 | NR4A2 2924/4885PDE4D 3810/4885NR1I2 2014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.